Introduction

In the last decades, the interest of molecular oncologists has been focused on the evolving pathways of cancer metastasis, fuelled by the possibility to isolate circulating tumor cells (CTCs) in the blood of cancer patients (1-3). Studies performed on cells forming a tumor have demonstrated that epithelial tumor cells exhibit epithelial properties and express on their surface molecules of epithelial origin (4). The ubiquitous expression of the epithelial cell adhesion molecule (EpCAM) in epithelial tumor cells allows to differentiate CTCs from blood cells and represents the rationale for the establishment of the so-called EpCAM based methods for the isolation of CTCs. To date, it seems clear enough that CTCs are highly heterogeneous and dynamically change their shape. Thus, the inadequacy of epithelial cell adhesion molecule (EpCAM) as universal marker for CTCs detection seems unquestionable and alternative methods able to recognize a broader spectrum of phenotypes are definitely needed. In this review the pleiotropic functions of EpCAM are discussed in detail and the role of the molecule in the biology of CTCs is critically dissected.

Keywords: Epithelial cell adhesion molecule (EpCAM); circulating tumor cells (CTCs); epithelial-mesenchymal transition; EpICD
EpCAM: a mainstay in CTC detection

The EpCAM (CD326) is a cell surface glycoprotein, originally identified as tumor antigen, being highly expressed in epithelial cancers and at lower levels in normal epithelia (15). The contemporary discovery of this molecule by different research groups, led to the use of different names for the same molecule, based on monoclonal antibodies or cDNA clones (16). In 2007, in a two days meeting focused on EpCAMs, “EpCAM” has been unanimously suggested as exclusive name (17).

EpCAM is a type I transmembrane glycoprotein of about 39–42 KDa, containing three N-glycosylation sites (6,10) all glycosylated as demonstrated in human and murine cell lines, although glycosylation of Asn198 seems to be of high importance for EpCAM’s cell surface expression and protein stability (18).

EpCAM forms a complex called tetraspanin-enriched microdomains (TEMs) with tetraspanins CD9 and CO-029 (tetraspanin8), and with CD44v4-7 variant isoform (19). This complex promotes EpCAM-specific functions as apoptosis resistance, cell proliferation and tumorigenicity (19,20). Moreover association of EpCAM, Claudin7 and TEMs, rather than the individual molecules promotes tumor progression and facilitates metastasis formation in colorectal cancer (21,22).

To date, our knowledge derived from more than 10 years of cancer research studies, indicates that EpCAM can act as either a tumor promoter or suppressor in human cancers depending on the type of cancer and the tumor microenvironment (23); however the presence of this molecule has been the main feature used to isolate CTC in the EpCAM era.

Although many EpCAM-based approaches have been developed and used in exploring CTCs, the detection rate of these rare cells seems critically dependent on the EpCAM clone used.

Antolovic et al. in 2010 demonstrated that the use of different anti EpCAM antibodies may lead to a heterogeneous detection of CTCs in patients with colorectal cancer employing immunomagnetic enrichment with mAb BerEP4 and mAb KS1/4 (24).

EpCAM era was characterized by studies performed by different assays all with the common aim to identify epithelial cells circulating within the blood through the expression of this surface EpCAM. Many assays have been widely developed for CTC enrichment and isolation each one with strength and weakness points.

CellSearch is the only FDA approved method used to obtain prognostic information through CTC count. CellSearch® assay was validated from Allard et al. for sensitivity, accuracy, and reproducibility (25). Using the CellSearch® assay, the prognostic value of CTC enumeration in metastatic breast (12,26-28), prostate (13,29) and colon cancer patients has been demonstrated (14,30). In patients with metastatic disease, superior survival was observed among patients with breast and colorectal cancer with a count of CTC fewer than five in a blood sample of 7.5 mL; for metastatic colorectal cancer patients the cut-off value was established <3 CTCs/7.5 mL. The clinical utility of this assay has also been demonstrated in metastatic small and non-small cell lung cancer (31,32), stomach cancer (33), pancreatic cancer (34), ovarian cancer (35), and in advanced (36) and non-muscle invasive bladder cancer (37,38).

According to the first CellSearch® training book, a CTC is characterized by positivity for EpCAM, cytokeratins (CKs), nuclear dye [DAPI (4',6-diamidino-2-phenylindole)] and negativity for CD45.

All images with delineated nuclear but speckled CK, or with cytoplasm area which does not surround the nucleus, are defined as “suspicious objects” and are not counted by the operator as CTCs. The predictive values of all types of suspicious objects were evaluated by Coumans et al. using the automated algorithm to identify and reanalyze all objects CD45−, EpCAM+, CK+, and/or DAPI−; all objects predicted OS in their cohort of 179 patients with castration-resistant prostate cancer (39).

Similar results were obtained in our laboratory using CellSearch analysis on renal cancer patients (40) and by other group in early and advanced NSCLC patients (41).

Another main strength of this assay is the possibility to perform an additional analysis with a monoclonal antibody of interest in the additional channel as first performed by Rossi et al. (42), using an anti M30 to recognize a neoepitope in CK-18 that becomes available at a caspase cleavage event during apoptosis (43,44). A device that collects the blood discarded after the EpCAM immunomagnetic detection by CellSearch system has been constructed to evaluate all EpCAM negative cells larger than 5 µm. These cells are filtered and immunostained to distinguish CTC from non-CTC. This innovative supplement offers the crucial advantage to recover all EpCAM-cells and to further perform immunostaining using different antibodies (45,46).

The clinical utility of CellSearch analysis as a prognostic test was definitively confirmed by Bidard et al., who recently
published the first European pooled analysis on clinical validity of CTC in 1,944 metastatic breast cancer patients treated between 2003 and mid-2012 in 17 centers. This is the largest pooled analysis, aimed to assess the clinical validity of CTC count by the standardized CellSearch® technique. The obtained results led to the conclusion that CTC count is an independent prognostic marker of PFS and OS while CA15-3 (carcinoembryonic antigen) and CA15-3 (cancer antigen 15-3) levels at baseline and during therapy did not add further significant information (47). Despite the prognostic value of CTC enumeration test, the lack of predictive ability to guide decision-making still represents the major obstacle for its validation in clinical practice. The randomized Phase III SWOG S0500 trial was designed to test whether persistently high CTC levels after the first cycle of therapy could be used as an early indicator of disease progression and to determine whether switching at that early point to an alternate chemotherapy regimen would result in improved survival and time to progression among patients with metastatic breast cancer. Although the study confirmed the prognostic value of CTCs, it failed to demonstrate the clinical utility of counting CTCs to evaluate the effectiveness of frontline chemotherapy in metastatic breast cancer patients (48).

Among the molecular-based techniques developed, AdnaTest is a series of commercially available assays that combines the immunomagnetic enrichment of tumor cells and a subsequent multiplex RT-PCR. The potential advantage of this approach is the possibility to simultaneously characterize cells for several additional markers.

In the first step, magnetic bead conjugated with antibody cocktail optimized for breast, colon, ovarian, prostate or EMT/stem cell are used. In the second, the expression of a set of molecular tumor markers is analyzed at RNA level.

Several studies have been performed with this technique, although the results appear discordant (7,49,50).

Although AdnaTest offers an enrichment step based to an additional marker, which is specific for tumor type and the advantage to deepen the molecular pattern of the enriched cells, the real value of this test, seems currently quite limited.

CTCs are isolated by immunomagnetic beads labelled with antibodies against MUC1 and EpCAM. However, MUC1 and EpCAM are also expressed by activated leukocytes, and the mRNA expression of these markers is, therefore, not restricted to CTCs (51) leading to false-positive findings. This test, as others commercially available for CTC detection, has not the potential to evolve as real fluid biopsy, due to its inability to offer live cells for morphological analysis.

For a long time, immunomagnetic separation (IMS) was performed using Dynabeads (52,53). These are magnetic beads coated with antibodies against specific cell surface antigens. Hardingham et al. used for the first time Dynabeads as EpCAM functionalized microposts to enhance cell-surface interactions. After this first Chip developed in the Massachusetts General Hospital by a trend group on CTC capture by this devices, others platform were generated: in 2011, one year later, the Herringbone chip has been developed in order to enhance the CTC recovery (58).

Other alternative devices as IsoFlux (59), MagSweeper (60) and GILUPI (61), all EpCAM based and with similar limitations to those of CellSearch, have been used, although some of them provide live CTCs, suitable for molecular analysis and in vitro expansion.

The possibility to capture, from large volumes of whole blood rare CTCs with both epithelial and non-epithelial characteristics has been object of study by Ozkumur et al. in 2013; in this work an inertial focusing-enhanced microfluidic CTC capture platform, termed “CTC-iChip” was described (62). The innovative characteristic of this chip is the ability of isolating CTCs using strategies that are either antigen dependent or independent and thus virtually applicable to all cancers. The authors demonstrated in patients with prostate, breast, colon, pancreatic, and lung cancer a very high sensitivity for the posCTC-iChip, particularly critical in patients with a lower CTC burden. Furthermore, the iChip is able to isolate cells in suspension, and their immobilization on a standard glass slide for clinical cytopathological examination and high-resolution imaging. The negative depletion of aberrant cells normally present in blood, which can be performed by iChip, allows the employ of this device, virtually to all cancers. Results obtained by the comparison between the posCTC-iChip and the CellSearch® system, demonstrated for the microfluidic device a higher sensitivity in capturing low...
CTC numbers suggesting that EpCAM-low CTCs were missed by the CellSearch® bulk-processing approach. An alternative approach for CTC capture which eliminates the issue of phenotypic surface marker heterogeneity is the Size-based isolation (63,64). The advantage of this method is the possibility to use isolated CTC for genomic or proteomic analysis; for this purpose ScreenCell®, ISET filters and more recently lithographic microfiltration have been employed (65-68). Isolation size based tests have the advantage to isolate live cells, which can be expanded in vitro or isolated to be further analyzed at molecular level. Mach et al. investigated on CTC trapping sensitivity and efficiency on cancer cells (69). In 2011 an inertial microfluidic size and deformability-based cell device for CTC enrichment was developed (70) and later, a Vortex Chip specific for high-purity extraction of cancer cells from blood sample was used (71). A novel three dimensional microfilter device that can enrich viable CTCs from blood from cancer patients was reported by Zheng et al. The device efficiency was investigated by cultured tumor cells spiked in blood with immunofluorescent staining, confocal and scanning electron microscopy (72).

**EpCAM: ianus bifrons in the biology of circulating tumor cells (CTCs)**

**EpCAM and EMT: a dynamic phenotype switching**

Since 2004, it has become evident that CTCs deserve attention as a biomarker for cancer disease and progression (12). From a biological perspective, CTCs represent a submicroscopic fraction detached from a primary tumor and in transit to a secondary site.

Similarly to intratumor heterogeneity, a certain degree of intercellular heterogeneity can be also envisaged within CTCs (5,6). One could imagine that CTCs recapitulate the Darwinian evolution of cancer, through the stepwise acquisition of genetic and epigenetic variations, followed by selective outgrowth of the fittest clones. Several lines of evidence have recently demonstrated that CTCs may adopt different strategies to protect themselves from the cell death fate, changing their phenotype from epithelial to mesenchymal, grouping into cell clusters or switching between the cancer stem cell state and the differentiated state of cancer cells (73). The dynamic evolution of CTCs phenotype might impair their detection, when antigen-dependent methods are used. Indeed, the EpCAM-based approach for the isolation of CTCs might underestimate the real CTCs burden, being unable to catch cells with a down-regulated expression of epithelial markers, as it happens when the EMT program is activated (74). A recent study by Yu et al. provided evidence of EMT in human breast cancer specimens, both in rare cells within primary tumors and in a significant number of CTCs, supporting a close link between EMT, CTCs and metastasis as components of a continuous multistep process (75). The aberrant activation of the EMT program leads to the down-regulation of proteins that support the epithelial architecture. As such, epithelial cancer cells loose cell–cell adhesion and polarity to become invasive and motile mesenchymal cells. Once detached from primary tumors, CTCs migrate as single cells or as part of cell clusters and then stay as dormant tumor cells or grow as a distant metastasis by the reverse process of EMT, the MET. The transient nature of the molecular changes that CTCs display during their lifetime leads to the hypothesis that EMT is sustained by reversible epigenetic regulatory mechanisms rather than permanent genetic alterations (76). The epithelial mesenchymal transition in CTCs might thus be conceived as a global reprogramming process, through which cells not only acquire invasion and migration competence, but also resistance to programmed cell death and stem cell-like functions (77).

**The dynamic regulation of EpCAM expression**

Human EpCAM is a transmembrane glycoprotein of 314 amino acids (aa), that functions as a homophilic, epithelial-specific intercellular cell-adhesion molecule, involved in the regulation of cell proliferation and differentiation. It consists of a large extracellular domain (N-terminal) of 242 aa, a single-spanning transmembrane domain of 23 aa and a short cytoplasmic domain of 26 aa (C-terminal) (78). Discovered as a dominant antigen on epithelia and invasive carcinomas, EpCAM was initially considered a mere cell adhesion molecule and became one of the most commonly used membrane-associated proteins for the isolation of CTCs from peripheral blood. Nevertheless, the observation that EpCAM can be downregulated during the dissemination of cancer cells from primary tumor through the bloodstream and that many epithelial tumors may lack EpCAM expression, rapidly suggested that EpCAM-based methods could be inadequate in the enrichment step of CTCs capture (79). That EpCAM expression is highly dynamic into the bloodstream was originally demonstrated in xenograft mouse models with EpCAM-expressing breast cancer cell lines, where
the intravenous injection of EpCAM expressing cells caused EpCAM downregulation 4 hours after the injection (7). Further studies widely demonstrated that EpCAM negative CTCs with mesenchymal cell like phenotype and downregulation of epithelial markers are frequently derived from EpCAM-positive primary tumors (80). Data are accumulating on the biology of EpCAM and increasing evidence indicates that the expression of EpCAM and its functional consequences are controlled by fine-tuned regulatory mechanisms. EpCAM can be transcriptionally downregulated by methylation of DNA at cytosine residues within CpG islands or can be mutated, although less frequently. Post-translational changes, such as glycosylation, have also been reported to influence the stability of EpCAM expression on epithelial cells membrane. The proteolytic cleavage of EpCAM is a further mechanism to fine-tune the dynamics of EpCAM expression. The membrane full length EpCAM protein, indeed, is subject to γ-secretase-dependent regulated intramembrane proteolysis (RIP), and proteasome-mediated degradation. Finally, endocytosis might be an additional means by which the EpCAM expression can be regulated (79,81).

Regulated intramembrane proteolysis (RIP) and EpCAM cleavage

The finding of a proteolytic cleavage of the EpCAM molecule in cancer cells led to the demonstration that a mechanism of RIP is able to activate EpCAM as a mitogenic signal transducer (82). Thus, a new role for EpCAM as mediator of proliferative signalling has been proposed. The cleavage of EpCAM, which is sequentially catalysed by TACE and presenilin-2, leads to the cleavage of the extracellular domain (EpEX) of the EpCAM molecule and to the consequent release of the short-lived intracellular domain (EpICD). After RIP, the intracellular EpICD is released in the cytoplasm and shuttles into the cell nucleus in a complex with the scaffold protein FH2 and β-catenin, inducing transcription of target genes, including c-myc, cyclins, stemness-inducing genes and genes related to cell proliferation (83). Shedding of EpEX during activation of EpCAM signalling produces a soluble ligand that can promote generation of EpICD in an autocrine or paracrine fashion. EpCAM expression and cleavage are both tightly regulated and only occur in case of a temporary need for cell proliferation. The nuclear localization of EpICD was first reported in human colon cancer and in different subtypes of thyroid cancers (84), where its presence was associated with some tumor aggressiveness and poor prognosis of patients. Hence, there is now growing evidence that subcellular compartmental accumulation of EpICD may be involved in development of epithelial carcinomas (85). Using anti-EpEX and anti-EpICD antibodies staining on tumour specimen, Fong et al. identified two EpCAM variants: the membrane-bound full-length protein (EpCAM Membranous full-length; EpCAMMF) and its truncated variant (EpCAM Membranous truncated; EpCAMMT) which lacks the intracellular domain but still has a remnant transmembranous and integral extracellular domain (86). Authors found that the ratio between EpCAMMF and EpCAMMT changed significantly depending on the tumor type. Proteolysis of EpCAM analyzed in different cancer types revealed strongest cleavage in cancers of the endometrium and the bladder, intermediate cleavage in gastrointestinal cancers, and low cleavage in lung, ovarian, breast and prostate tumors. Increased release of EpEX enhances EpICD cleavage resulting also in activation of epithelial-mesenchymal transition genes suggesting that EpICD might contribute to tumor initiation and progression. One of the consequences of EpCAM proteolysis is the withdrawal of the extracellular domain from the plasma membrane, which might account for the lack of EpCAM expression in CTCs from patients with aggressive tumor types. Being that the antibodies used for CTCs capture usually target the ectodomain of the antigen, they cannot discriminate between membrane-bound full-length EpCAM and cleaved variants. Indeed, the status of nuclear EpICD in CTCs lacking EpCAM ectodomain, thus being missed using EpCAM-based methods, has never been investigated and deserves further attention.

The functional consequences of EpCAM loss

From a theoretical point of view, the dynamic expression of EpCAM in cancer cells might be both the result of an aberrant activation of the EMT program, which in turn leads to an overall downregulation of epithelial markers, or can represent itself the initial trigger for the phenotype switching. The properties of EpCAM as a mitogenic signaling might favor this latter hypothesis (87). Indeed, among its plethora of functions, at least two might be advocated to support the hypothesis of EpCAM as a driving force for the phenotypic changes in the EMT/MET switch. EpCAM has been initially proposed as a homotypic cell adhesion molecule, contributing to the integrity of epithelial tissues. However, it has been demonstrated that
EpCAM can weaken E-cadherin-mediated intercellular adhesion, decreasing overall the strength of intercellular adhesive junctions (16). It has been also demonstrated that EpCAM directly regulates the induction of EMT, through the expression of Snail, Slug and vimentin (88). The induction of EMT has been shown to generate stem-like cells (89), which is somehow consistent with the observation that nuclear translocation of EpICD participates in stemness genes modulation, to maintain cell renewal and cell survival. The positive autoregulation of the EpCAM loop, maintained through the soluble fraction EpEX, which enhances the EpCAM cleavage and triggers the EpICD signaling, may ensure that EpCAM provides a sustained signal for proliferation, self-renewal, anchorage-independent growth and invasiveness (23). Overall, these observations lead to the hypothesis that the pleiotropic and apparently contradictory functions of EpCAM, might instead be tightly controlled to allow cancer cells to acquire phenotypic beneficial changes, which favor alternatively cell-cell adhesion and active proliferation or motility and stemness properties along the metastatic cascade.

**Take home messages**

CTCs are rare and multifaceted cells travelling from primary tumors to secondary sites. The dynamic changes in CTCs phenotype are increasingly being recognized and it is definitely apparent that CTCs represent a heterogeneous entity that lies beyond a univocal definition. Originally identified as a dominant antigen in epithelial cancers, EpCAM has been considered since the beginning the ideal marker for the detection of CTCs in the peripheral blood of cancer patients. However, over the last few years, a growing body of evidence has arisen supporting the plasticity of CTCs phenotype. As a consequence, a kaleidoscopic definition of CTCs is required and the establishment of a universal marker for their detection seems merely a vision. Conversely, the pleiotropic functions of EpCAM have been recently clarified and the definition of the biological role of this molecule in CTCs became complicated. So far, the experimental evidence of the dynamic expression of EpCAM in CTCs is limited to studies performed in order to demonstrate the limited sensitivity of EpCAM-based methods in the detection of CTCs in pre-defined subtypes or settings of disease. It is rather conceivable that the functional consequences of EpCAM loss need to be investigated to understand what happens to CTCs when they undergo to the global reprogramming process that includes the epithelial to mesenchymal switch and the transient acquisition of stemness properties. Some new technologies, mainly CTC-chip and high-definition (HD)-CTC assays, relying upon EpCAM independent enrichment of the entire CTC population, seem the optimal candidates for future fluid biopsies, being able to measure gene expression, DNA mutations and to capture live cells for conventional histological analysis.

Even in the current post EpCAM era the crucial role of EpCAM molecule in CTC detection cannot be neglected. The prognostic significance of EpCAM positive CTCs, which was recently confirmed by the first European pooled analysis in metastatic breast cancer, is a undisputable evidence. Nevertheless, the increasing evidence of CTCs heterogeneity, which, similarly to what described in primary tumors, likely evolves during the disease course, needs to be further investigated.

In addition to difficulties to pinpoint an antibody combination to cover the complex heterogeneity of CTCs, avoiding false negative results, there are at least three more questions to be addressed: (I) some systems are very expensive; this bias automatically exclude some research groups; (II) each system used for the enrichment step has different sensitivity and (III) there is necessity to standardize each method. In the post-EpCAM era we have the feeling that no single marker will be sufficient to isolate the entire pool of CTC, as well as no marker combination will be sufficient to cover the extreme heterogeneity of these cells in different tumor types. Whether EpCAM cleavage might represent a beneficial change for CTCs to survive, proliferate and acquire stem-like features deserves to be deepened.

**Acknowledgements**

None.

**Footnote**

*Conflicts of Interest:* The authors have no conflicts of interest to declare.

**References**

1. Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aus Med J 1869;14:146-9.
2. Engell HC. Cancer cells in the circulating blood; a clinical


